B
Braidwell Portfolio holdings
AUM
$2.7B
Turnover
43.12%
1-Year Est. Return
88.53%
This Fund
S&P 500
This Quarter
Est. Return
+31.47%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.7B
AUM Growth
-$294M
(-9.8%)
Cap. Flow
-$772M
Cap. Flow
% of AUM
-28.57%
Top 10 Holdings %
Top 10 Hldgs %
31.56%
Holding
109
New
24
Increased
20
Reduced
34
Closed
23
Avg Time Held
0.9
years
Top 10 Avg Time Held
0.4
years
Top 20 Avg Time Held
0.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphatec Holdings
ATEC
|
+$39.7M |
| 2 |
Humana
HUM
|
+$32.6M |
| 3 |
Maze Therapeutics
MAZE
|
+$29.9M |
| 4 |
Avalo Therapeutics
AVTX
|
+$25.8M |
| 5 |
Alamar Biosciences
ALMR
|
+$24.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$78.9M |
| 2 |
Nuvalent
NUVL
|
+$71.8M |
| 3 |
CG Oncology
CGON
|
+$66.7M |
| 4 |
argenx
ARGX
|
+$55.5M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$46.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.44% |
| 2 | Miscellaneous | 3.68% |
| 3 | Financials | 0.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Elevance Health
ELV
$92.8B
| $20.9M | 0.77% |
53,960
-8,120
| -13% | -$3.01M |
2026 Q1
1 quarter
|
|
52
Tectonic Therapeutic
TECX
$410M
| $20.5M | 0.76% |
596,900
-250,251
| -30% | -$7.35M |
2025 Q3
3 quarters
|
|
53
Dyne Therapeutics
DYN
$2.81B
| $20.5M | 0.76% |
921,598
-760,400
| -45% | -$14.1M |
2024 Q4
6 quarters
|
|
54
Immunocore
IMCR
$1.46B
| $16.6M | 0.61% |
+521,327
| New | +$15.4M |
2026 Q2
0 quarters
|
|
|
55
argenx
ARGX
$51.5B
| $16.4M | 0.61% |
17,707
-67,232
| -79% | -$55.5M |
2023 Q4
10 quarters
|
|
56
Celldex Therapeutics
CLDX
$2.19B
| $16.2M | 0.6% |
436,646
-919,436
| -68% | -$29.7M |
2025 Q3
3 quarters
|
|
57
Ovid Therapeutics
OVID
$428M
| $15.9M | 0.59% |
+5,919,464
| New | +$15.3M |
2026 Q2
0 quarters
|
|
58
MannKind Corp
MNKD
$971M
| $14.7M | 0.55% |
+3,458,429
| New | +$11.2M |
2026 Q2
0 quarters
|
|
59
uniQure
QURE
$1.45B
| $13.9M | 0.51% |
+301,652
| New | +$7.9M |
2026 Q2
0 quarters
|
|
60
X4 Pharmaceuticals
XFOR
$243M
| $13.6M | 0.5% |
2,922,754
-350,200
| -11% | -$1.44M |
2025 Q4
2 quarters
|
|
61
Oric Pharmaceuticals
ORIC
$1.2B
| $13.2M | 0.49% |
1,214,540
+86,500
| +8% | +$784K |
2026 Q1
1 quarter
|
|
62
Kiniksa Pharmaceuticals
KNSA
$6.15B
| $11.8M | 0.43% |
183,822
-88,700
| -33% | -$4.6M |
2024 Q1
9 quarters
|
|
63
Oculis Holding
OCS
$442M
| $11.6M | 0.43% |
+834,183
| New | +$18.9M |
2026 Q2
0 quarters
|
|
64
Aclaris Therapeutics
ACRS
$498M
| $11.3M | 0.42% |
2,142,348
+443,232
| +26% | +$1.98M |
2026 Q1
1 quarter
|
|
65
Seaport Therapeutics
SPTX
$893M
| $10.9M | 0.4% |
+500,000
| New | +$8.8M |
2026 Q2
0 quarters
|
|
66
Vor Biopharma
VOR
$1.11B
| $10.6M | 0.39% |
573,104
+106,330
| +23% | +$1.61M |
2026 Q1
1 quarter
|
|
67
Surrozen
SRZN
$279M
| $10.1M | 0.38% |
390,753
-5,347
| -1% | -$147K |
2025 Q2
4 quarters
|
|
68
Immunic
IMUX
$90.9M
| $9.91M | 0.37% |
+645,010
| New | +$7.96M |
2026 Q2
0 quarters
|
|
69
Helix Acquisition Corp III
HLXC
$229M
| $9.54M | 0.35% |
900,000
| – | – |
2026 Q1
1 quarter
|
|
70
Ionis Pharmaceuticals
IONS
$7.1B
| $9.26M | 0.34% |
116,762
-14,100
| -11% | -$1.06M |
2026 Q1
1 quarter
|
|
71
Quest Diagnostics
DGX
$25.8B
| $9.16M | 0.34% |
+43,200
| New | +$8.48M |
2026 Q2
0 quarters
|
|
72
Adlai Nortye Group ADS
ANL
$701M
| $9.14M | 0.34% |
+795,214
| New | +$9.68M |
2026 Q2
0 quarters
|
|
73
Tenax Therapeutics
TENX
$57.3M
| $8.5M | 0.31% |
+584,412
| New | +$7.47M |
2026 Q2
0 quarters
|
|
|
KARD
74
Kardigan Inc
KARD
$1.26B
| $7.16M | 0.26% |
+300,000
| New | +$6.94M |
2026 Q2
0 quarters
|
|
75
Amanat Acquisition Corp
AMAN
$100M
| $7.11M | 0.26% |
+700,000
| New | +$7.07M |
2026 Q2
0 quarters
|
|
Similar funds
M
AG
NIM
GC
CCM
ACP
GBCP
SCM
Braidwell's Q2 2026 Portfolio in Review
As of Q2 2026, Braidwell held 109 positions worth $2.7B, down 9.8% from $3B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Braidwell withdrew a net $772M in Q2 2026, closing 23 positions and reducing 34 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $78.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 87% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Braidwell opened a new position in Humana worth $45.5M.
- Braidwell's largest Q2 2026 buy was Humana: 114,500 shares worth $45.5M.
- Braidwell added most to Alphatec Holdings in Q2 2026, an estimated $39.7M increase.
- Braidwell's biggest Q2 2026 reduction was argenx, cutting an estimated $55.5M.
- Braidwell fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $78.9M.
- Braidwell's ten largest holdings make up 32% of its $2.7B portfolio in Q2 2026.
- Braidwell opened 24 new positions and closed 23 in Q2 2026.
- Braidwell's portfolio value fell 9.8% quarter-over-quarter to $2.7B.
Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.